Cardiome Pharma (CRME) Earning Somewhat Positive News Coverage, Accern Reports

Media headlines about Cardiome Pharma (NASDAQ:CRME) (TSE:COM) have been trending somewhat positive on Sunday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cardiome Pharma earned a coverage optimism score of 0.23 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.0958050577664 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Cardiome Pharma (CRME) traded up $0.04 during trading hours on Friday, hitting $1.47. The stock had a trading volume of 12,563 shares, compared to its average volume of 69,773. The company has a market capitalization of $50.90, a price-to-earnings ratio of -1.75 and a beta of 0.59. Cardiome Pharma has a 52 week low of $1.29 and a 52 week high of $4.84. The company has a debt-to-equity ratio of 1.67, a current ratio of 5.52 and a quick ratio of 4.71.

CRME has been the subject of several research analyst reports. Zacks Investment Research lowered Cardiome Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, November 14th. Canaccord Genuity set a $5.00 price objective on Cardiome Pharma and gave the company a “buy” rating in a report on Wednesday, November 15th. Mackie raised Cardiome Pharma to a “buy” rating in a report on Friday, December 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $9.50 target price on shares of Cardiome Pharma in a report on Wednesday, November 22nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $5.50.

ILLEGAL ACTIVITY WARNING: “Cardiome Pharma (CRME) Earning Somewhat Positive News Coverage, Accern Reports” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/18/cardiome-pharma-crme-earning-somewhat-positive-news-coverage-accern-reports.html.

Cardiome Pharma Company Profile

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.

Insider Buying and Selling by Quarter for Cardiome Pharma (NASDAQ:CRME)

Receive News & Ratings for Cardiome Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply